Mizuho downgraded BioXcel Therapeutics to Neutral from Buy with a price target of $4, down from $40.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BTAI: